Table of Contents
Overview
Definition of Immunotherapy
Immunotherapy is a groundbreaking approach to cancer treatment that leverages the body's immune system to identify and eliminate malignant cells while sparing healthy tissues. This method involves enhancing or stimulating the immune system's natural capabilities to recognize and destroy cancer cells, marking a significant advancement in oncology.[1.1] The historical development of immunotherapy can be traced from early observations of immune responses against tumors to its eventual integration into modern oncology treatments. As advancements in microscopy and pathology emerged in the early 20th century, researchers began to identify immune cells infiltrating tumors, which raised questions about their function in cancer biology.[2.1] The idea of using immunotherapy in cancer gained renewed prominence in 1957 when Thomas and Burnet proposed the theory of cancer immunosurveillance, highlighting the immune system's role in recognizing and eliminating cancer cells.[4.1] This foundational concept paved the way for the incorporation of various immune-based treatments, including IL-2 antibody therapies, checkpoint inhibitors, and monoclonal antibodies, into clinical practice, often tailored to individual tumor biomarkers and genetic profiles.[2.1] Immunotherapy is often perceived as a relatively recent advance; however, its origins can be traced back to antiquity, where early attempts to modulate the immune system for cancer treatment were made under different names.[5.1] Significant progress in the field was marked by the discovery of T cells in 1967, which revealed their crucial role in immunity and catalyzed research into modern cancer immunotherapy.[6.1] Clinical trials have demonstrated that biological response modifier (BRM) therapy, also known as biologic therapy, biotherapy, or immunotherapy, is effective for many types of cancer, with some biologic agents being naturally occurring in the body and others developed in the laboratory.[7.1] Recent advancements have further refined immunotherapy, particularly through the characterization of tumor-infiltrating immune cells and their therapeutic implications. This ongoing research aims to enhance the effectiveness of immunotherapy, although the response rates can vary significantly among different cancer types.[8.1] Overall, immunotherapy represents a monumental breakthrough in cancer treatment, fundamentally altering the landscape of oncology and offering new hope for patients.[3.1]Mechanisms of Action
Immunotherapy operates through various mechanisms that enhance the immune system's ability to recognize and eliminate cancer cells. One of the foundational concepts in this field is cancer immunoediting, which describes the dynamic interaction between tumor cells and the immune system within the tumor microenvironment (TME). This process consists of three distinct phases: elimination, equilibrium, and escape, wherein the immune system can both protect against cancer development and inadvertently shape tumor evolution.[45.1] Recent advancements in immunotherapy have focused on leveraging immune checkpoint inhibitors (ICIs) and chimeric antigen receptor (CAR) T-cell therapy. ICIs, such as PD-1/PD-L1 and CTLA-4 inhibitors, work by enhancing the immune response against tumors, thereby providing significant clinical benefits in various cancers, including melanoma and non-small-cell lung cancer.[15.1] These therapies aim to overcome the inhibitory signals that tumors use to evade immune detection, allowing T cells to become re-activated and effectively eliminate cancer cells through the release of cytokines and cytolytic mechanisms.[44.1] Recent advances in cancer immunotherapy, particularly through the use of immune checkpoint inhibitors (ICIs) and chimeric antigen receptor (CAR) T-cell therapy, have significantly enhanced the clinical management of various cancers. ICIs, such as PD-1/PD-L1 and CTLA-4 inhibitors, improve the body's immune response against tumors, providing substantial benefits in treating cancers like melanoma, non-small-cell lung cancer, and lymphoma.[15.1] Ongoing research is investigating combination therapies that integrate ICIs with CAR T-cell therapy, alongside improved CAR T-cell engineering and strategies to modulate the tumor microenvironment, which aim to enhance immune cell infiltration and function within tumors.[15.1] Additionally, thematic analysis has identified immunosenescence and its implications for immunotherapy as prominent research hotspots, indicating a growing focus on understanding how the aging immune system affects treatment efficacy.[14.1] The interplay between the immune system and cancer is further elucidated by the concept of cancer immunoediting, which emphasizes the necessity of understanding local immune responses within the TME to identify mechanisms of immunotherapy resistance and develop strategies to overcome these challenges.[44.1] As research continues to evolve, the integration of these insights into clinical practice is expected to solidify immunotherapy's role as a cornerstone of cancer treatment.[13.1]History
Milestones in Immunotherapy Development
The development of immunotherapy has been marked by several significant milestones that have shaped its evolution as a treatment modality for cancer. The journey began in 1890 with the discovery of serum therapy for infectious diseases, which laid the groundwork for future immunotherapeutic approaches.[47.1] In the following decades, particularly during the 1930s and 1940s, researchers explored the use of bacteria to treat tumors, achieving intermittent success by inducing necrosis in cancerous tissues.[48.1] The concept of immunotherapy gained further traction in 1957 when the theory of cancer immunosurveillance was proposed by Thomas and Burnet, suggesting that the immune system plays a critical role in identifying and eliminating cancer cells.[4.1] This theoretical framework set the stage for subsequent advancements in the field. The development of immunotherapy has a rich history, with significant milestones marking its evolution. Tumor necrosis factor (TNF) was identified as a cancer immunotherapy in the 1970s, representing a major advancement in the field.[48.1] In recent years, particularly over the last decade, the clinical landscape has transformed dramatically with the emergence of active immunotherapies. Notably, immune checkpoint inhibitors (ICIs), such as PD-1 and PD-L1, have been integrated into standard-of-care treatments for various cancer types.[49.1] This rapid development underscores the growing importance of immunotherapy in oncology. Recent years have witnessed an explosion in the clinical development of immunotherapies, with a focus on understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications.[3.1] The integration of these therapies into oncology has been facilitated by advancements in laboratory techniques and clinical applications, allowing for a more tailored approach to cancer treatment based on individual tumor profiles.[53.1]Recent Advancements
Innovations in Treatment Approaches
Recent advancements in immunotherapy have led to the emergence of innovative treatment approaches that significantly enhance cancer management. Cancer immunotherapy, which engages the immune system to recognize and eliminate cancer cells, has become a distinct pillar of cancer therapy. Among the most promising modalities are therapeutic vaccines, immune checkpoint blockade, bispecific T-cell engagers (BiTEs), and adoptive cell therapies, all of which share a common mechanism of action aimed at stimulating the immune response against tumors.[95.1] The landscape of immunotherapy is continually evolving, with a notable shift from traditional therapies to newer modalities. Recent analyses indicate that while the number of new immuno-oncology (IO) clinical trials has decreased for the first time since 2018, there is a record number of IO targets being investigated, with 195 targets currently in clinical trials.[102.1] This shift reflects an improved understanding of cancer pathogenesis, which has facilitated the development of targeted agents alongside immunotherapy.[101.1] Personalized medicine is also playing a crucial role in the evolution of immunotherapy. By harnessing the specific characteristics of individual tumors, personalized therapies aim to achieve better clinical outcomes compared to traditional treatment approaches. For instance, adoptive cell therapy and neoantigen vaccines exemplify how the immune system can be tailored to enhance therapeutic efficacy.[96.1] Clinical trials have demonstrated that patients with DNA repair gene mutations, which result in higher tumor mutational burden (TMB), exhibit significantly better recurrence-free survival rates.[98.1] Furthermore, recent studies involving personalized neoantigen vaccines have shown promising results, with objective response rates of 59%, 39%, and 27% in melanoma, non-small cell lung cancer (NSCLC), and bladder cancer, respectively.[98.1] Immunotherapy has also shown remarkable success in treating advanced cancers such as lung cancer, melanoma, and advanced bladder and kidney cancer, with the list of treatable cancers continuing to expand as more drugs undergo clinical trials.[94.1] Unlike traditional chemotherapies that directly target cancer cells, immunotherapy enhances the innate immune response, providing a more targeted and potentially longer-lasting effect with fewer side effects.[99.1] This innovative approach is increasingly being integrated into first-line treatments for various cancers, demonstrating significant benefits for patients who have not responded well to conventional therapies.[100.1]Challenges and Future Directions
The field of immunotherapy faces several significant challenges that must be addressed to enhance its efficacy and accessibility. One major hurdle is the limitations of current animal models, which often fail to accurately predict the efficacy of immunotherapy strategies in humans. This discrepancy complicates the transition from laboratory studies to clinical trials, as researchers struggle to establish reliable preclinical findings that can be translated into effective treatments for patients.[116.1] Additionally, the complexity of cancer, characterized by tumor heterogeneity and immune escape mechanisms, presents another significant challenge in developing effective immunotherapeutic agents.[115.1] Traditional clinical trial designs have faced significant limitations due to the rapid increase in knowledge and pharmaceutical development, particularly the pharmacological differences in toxicity profiles and effectiveness patterns between immunotherapy and chemotherapy. This evolution in trial designs is necessary to address these emerging challenges.[117.1] Among the key hurdles identified in the transition from laboratory studies to clinical trials are the limitations of current animal models to predict the efficacy of cancer immunotherapy strategies in humans, prolonged approval times for initiating clinical trials, and the complexity of cancer, including tumor heterogeneity and immune escape.[115.1] Additionally, the lack of definitive biomarkers for assessing the clinical efficacy of cancer immunotherapies complicates the evaluation of treatment responses and the identification of optimal therapeutic combinations.[115.1] Addressing these challenges will require collaborative efforts from both basic researchers and clinicians, focusing resources to enhance the understanding of the complex interactions between cancer and the immune system.[116.1] Patient experiences and feedback are crucial for informing future research and development in the field of immunotherapy, particularly regarding immune checkpoint inhibitors (ICIs). A systematic review has indicated that while an increasing number of patients are considering or undergoing immunotherapy, there remains a limited understanding of their perspectives on this treatment.[126.1] The review identified three analytical themes: decision-making related to treatment, the experiences and impacts of receiving ICIs, and the appraisal of immune-related adverse events (irAEs).[124.1] These findings reveal significant unmet information, psychological, and practical support needs among patients, emphasizing the necessity of understanding their treatment experiences to ensure safe and effective person-centered care.[125.1] Furthermore, it has been observed that existing cancer decision-making pathways often prioritize clinical management over patients' preferences and priorities, highlighting a notable gap in the literature concerning the immunotherapy decision-making process across various tumor sites and stages of disease.[127.1] This underscores the urgent need for more inclusive frameworks that take patient priorities into account in the development of treatment protocols. As the field continues to evolve, addressing these challenges will require collaborative efforts between basic researchers and clinicians, focusing on the complex interactions between cancer and the immune system. By overcoming these obstacles, the potential for improved treatment options and outcomes for patients with cancer can be realized.[116.1]In this section:
Types Of Immunotherapy
Monoclonal Antibodies
Monoclonal antibodies represent a crucial category of immunotherapy utilized in cancer treatment. These targeted antibodies are designed to disrupt the activity of cancer cells and alert the immune system to their presence.[134.1] Immunotherapy enhances the immune system's ability to combat cancer, and various types of immunotherapy, including monoclonal antibodies, have been approved for treating numerous cancer types.[135.1] By facilitating a more effective immune response, these therapies contribute significantly to the overall strategy of cancer management. Immunotherapy represents a significant advancement in cancer treatment, as it encompasses a variety of approaches that harness the body's own immune system to combat malignancies.[136.1] This umbrella term includes the use of drugs, biological agents such as monoclonal antibodies and cytokines, as well as vitamins, minerals, transplantation, and immunizations.[137.1] The primary goal of immunotherapy is to modulate immune responses, either by upregulating or downregulating them, to achieve therapeutic effects in various immunologically mediated disorders, including cancer.[137.1] By employing these diverse modalities, immunotherapy aims to improve the quality of life and life expectancy for patients suffering from a range of conditions, including malignancies and autoimmune diseases.[137.1] Monoclonal antibodies are a significant component of cancer immunotherapy, classified under targeted antibodies, which can disrupt cancer cell activity and alert the immune system to the presence of cancer cells.[134.1] This type of immunotherapy enhances the body's natural defenses against cancer, contributing to improved treatment outcomes. Various forms of immunotherapy, including cancer vaccines and oncolytic virus therapy, further complement the role of monoclonal antibodies by educating the immune system about cancer cells and utilizing viruses that specifically target and destroy cancer cells, respectively.[134.1] Overall, the integration of monoclonal antibodies into cancer treatment strategies represents a powerful advancement in the fight against cancer, aiming to improve patient survival rates and quality of life.CAR T-cell Therapy
CAR T-cell therapy is a groundbreaking form of cancer immunotherapy that utilizes genetically engineered T cells to target and eliminate cancer cells. This approach has shown significant promise, particularly in the treatment of hematological malignancies. As of July 31, 2023, the U.S. Food and Drug Administration (FDA) has approved six distinct CAR T-cell therapies, which are designed to enhance the body’s immune response against various types of blood cancers.[147.1] Chimeric antigen receptor (CAR) T-cell therapy represents a significant advancement in cancer immunotherapy, particularly for hematological malignancies.[134.1] This innovative approach involves the use of genetically engineered T cells that can recognize tumor antigens, enhancing the immune response against cancer.[135.1] The importance of the interaction between cancer cells and immune cells has been increasingly acknowledged, highlighting the role of these engineered T cells in effective cancer treatment.[135.1] As a result, CAR T-cell therapies have emerged as a promising option in the landscape of cancer immunotherapy, contributing to improved treatment outcomes for patients with specific blood cancers.[134.1] Immunotherapy has emerged as an advanced treatment approach for a range of cancers, including both hematological malignancies and solid tumors. This strategy harnesses the patient's immune system to combat cancer, offering a pathway to more targeted and efficient treatments. Compared to traditional chemotherapy, immunotherapy is associated with fewer side effects, making it a promising therapeutic option.[149.1] Although immunotherapies have shown promise in treating non-small cell lung cancer (NSCLC), many patients still do not respond well, and those who do may eventually develop resistance.[163.1]In this section:
Efficacy And Outcomes
Survival Rates and Progression-Free Survival
Immunotherapy has shown significant promise in improving survival rates and progression-free survival among cancer patients, particularly those who have not responded to first-line therapies. Studies indicate that the use of immunotherapy, whether as a standalone treatment or in conjunction with conventional cancer therapies, can enhance overall survival and progression-free survival rates, especially in patients experiencing disease recurrence after initial treatments.[178.1] The efficacy of immunotherapy, particularly immune checkpoint inhibitors (ICIs), varies significantly across different cancer types. For example, the objective response rates for single-agent PD-1 inhibitors range from almost nonexistent in pancreatic cancer and microsatellite-stable colonic adenocarcinoma to an average of 15%–30% in most other tumor types. In contrast, cancers such as melanoma, Hodgkin lymphoma, squamous-cell carcinoma of the skin, and Merkel cell carcinoma exhibit much higher response rates, ranging from 50% to 80%.[183.1] Furthermore, results from a phase 3 trial of immunotherapy with an anti-PD-1-based therapy demonstrated a continued long-term survival benefit in patients with advanced melanoma, with a median overall survival of 71.9 months (approximately 6 years) after a follow-up of at least 10 years.[185.1] This underscores the potential for long-term benefits of immunotherapy in certain malignancies. In the context of non-small cell lung cancer (NSCLC), immunotherapy has been validated as beneficial for patients with brain metastases, with treatments showing superior efficacy compared to those who have not received immunotherapy.[186.1] The long-term survival benefits of immunotherapy are further supported by findings from large international studies, which indicate that immunotherapy can significantly improve long-term overall survival in advanced melanoma patients.[184.1] Moreover, researchers have identified several key factors that influence the response to immunotherapy, including tumor mutational burden, T-cell infiltration, and previous treatment history. These factors can help tailor immunotherapy approaches to enhance patient outcomes and survival rates.[187.1] Overall, the advancements in immunotherapy represent a monumental breakthrough in cancer treatment, offering hope for improved survival and quality of life for many patients.Comparison with Traditional Treatments
Immunotherapy has shown promising long-term benefits compared to traditional treatments for various cancers, particularly advanced non-small cell lung cancer (NSCLC) and melanoma. In a follow-up study of NSCLC patients treated with nivolumab, approximately 16% were still alive five years after treatment initiation, a significant improvement over the expected survival rate of 5% for similar patients in the US population.[188.1] This suggests that immunotherapy may provide substantial long-term survival advantages that traditional therapies may not achieve. Moreover, large international studies have indicated that immunotherapy enhances overall survival rates in patients with advanced melanoma, reinforcing its potential as a more effective treatment option compared to conventional therapies.[189.1] The ability of immunotherapy to enable the immune system to recognize and destroy cancer cells marks a fundamental shift in cancer treatment paradigms, offering a mechanism that traditional treatments, such as chemotherapy and radiation, do not utilize. Cost-effectiveness is a significant factor when evaluating immunotherapy in comparison to traditional treatments for non-small cell lung cancer (NSCLC). A major concern regarding immunotherapy is its high cost, with nivolumab costing approximately $24.69 per milligram, leading to an annual treatment expense that can reach up to $134,807.[191.1] However, immunotherapy can be a cost-effective option in several scenarios, particularly when strategies such as applying a discount on agents or utilizing PD-L1 expression as a biomarker are implemented to enhance its cost-effectiveness.[190.1] Notably, among the NSCLC studies reviewed, 21 out of 35 demonstrated that pembrolizumab, when used as a first-line treatment following PD-L1 assessment, was cost-effective at a threshold of $100,000 per quality-adjusted life year (QALY) compared to standard care.[192.1] These findings underscore the potential for immunotherapy to be economically viable under specific conditions, thereby improving access while maintaining sustainability in healthcare systems.[190.1]Side Effects And Management
Strategies for Managing Adverse Effects
A comprehensive management plan is essential for addressing the side effects associated with immunotherapy. Patients should be informed about potential side effects and develop a management strategy in collaboration with their cancer care team. This proactive approach can help patients feel more in control and alleviate anxiety related to treatment.[221.1] Immunotherapy is a form of cancer treatment that utilizes the body's immune system to target and destroy cancer cells. While it is designed to enhance immune responses against cancer, immunotherapy can also lead to a range of side effects that differ from those associated with traditional chemotherapy.[223.1] Common side effects include fatigue, which may be attributed to changes in thyroid function, and immune-related (IR) colitis, characterized by inflammation of the large intestine, which manifests as diarrhea.[229.1] Additionally, the heightened activity of the immune system can inadvertently result in inflammation of healthy tissues, leading to various adverse effects.[224.1] Understanding these side effects is crucial for effective management and improving patient outcomes during immunotherapy treatment.[224.1] To effectively manage these side effects, healthcare providers are encouraged to utilize established guidelines, such as those from the European Society for Medical Oncology (ESMO), which outline the grading and management of immune-related adverse events (irAEs).[225.1] These guidelines provide a framework for clinicians to identify and address the specific toxicities associated with immune checkpoint inhibitors and other immunotherapy modalities. Immunotherapy can have significant psychological and emotional effects on patients undergoing treatment, including anxiety, depression, and mood swings.[230.1] A clearer understanding of the sources of anxiety for those undergoing immunotherapy is crucial, as anxiety during cancer treatment can lead to decreased treatment adherence and other negative outcomes.[231.1] Therefore, it is important for patients to be aware of these potential side effects and to seek support from their loved ones and healthcare professionals.[230.1] Understanding side effects encompasses not only clinical considerations but also emotional, social, and psychological aspects of patient care. This patient-centric approach enables healthcare providers to tailor treatments that best suit individual needs, ultimately improving overall well-being and treatment outcomes.[226.1]Current Research And Clinical Trials
Ongoing Studies
Recent trends in ongoing studies of immunotherapy indicate a significant shift in the landscape of clinical trials. According to the Cancer Research Institute's 2023 update, there has been a notable decrease in the number of new immuno-oncology (IO) trials, marking the first decline since the analysis began in 2018. Specifically, there was a 2.86% decrease in new trials in 2022 compared to the previous year, primarily driven by a 6.4% reduction in phase 2 trials. Despite this decline, the number of investigational IO targets has reached a record high of 195, reflecting an expansion in the scope of IO-based therapies.[260.1] In addition to the overall trends, specific breakthroughs in immunotherapy are being reported. For instance, a groundbreaking clinical trial demonstrated that an immune checkpoint inhibitor could lead to a complete clinical response in patients with locally advanced rectal cancer, effectively sparing them from chemoradiotherapy and surgery.[262.1] This highlights the potential of immunotherapy to transform treatment paradigms for certain cancer types. Moreover, ongoing research is focusing on combination therapies that integrate immune checkpoint inhibitors (ICIs) with chimeric antigen receptor (CAR) T-cell therapy. This approach aims to enhance the immune response against tumors and improve clinical outcomes across various cancers.[263.1] The exploration of these innovative strategies is crucial, as they may address some of the limitations associated with traditional therapies. However, the field of immunotherapy also faces significant challenges. Issues such as immunotherapy resistance, variability in patient responses, and the need for improved biomarkers hinder its widespread success.[291.1] A comprehensive analysis has identified nine major hurdles in advancing cancer immunotherapy, including limitations of current animal models, prolonged approval times for clinical trials, and the complexity of cancer itself.[292.1] Addressing these challenges is essential for translating the biological mechanisms of immunotherapy into effective clinical applications.Emerging Therapies
Emerging therapies in immunotherapy are increasingly focused on the identification and utilization of novel targets to enhance treatment efficacy. Mass spectrometry has been instrumental in the direct and unbiased discovery of tumor-specific human leukocyte antigen (HLA) peptides, which can be leveraged to define targets for immunotherapy. This approach facilitates the creation of a multi-target therapy warehouse, thereby accelerating clinical applications of these therapies.[265.1] Recent studies have highlighted the significance of mutational burden in predicting patient responses to immunotherapy. For instance, a novel method developed by Roszik et al. utilizes a small next-generation sequencing (NGS) panel to predict total mutational load, demonstrating a strong correlation with outcomes in melanoma and non-small cell lung cancer (NSCLC).[266.1] This predictive capability is crucial for optimizing patient selection in clinical trials. Moreover, the integration of immune checkpoint inhibitors, such as LAG3 and TIGIT blockade, is being explored to address emerging challenges like treatment resistance and adverse effects. These innovative combinations aim to enhance the overall efficacy of immunotherapy while identifying predictive biomarkers that can further refine patient selection.[267.1] In the realm of surgical oncology, the role of immunotherapy is set to expand as new immune checkpoints are actively evaluated in clinical trials. These include lymphocyte activation gene 3 (LAG3), T cell immunoreceptor with Ig and ITIM domains, and killer Ig-like receptor 2DL1/2L3, which represent promising avenues for future therapeutic strategies.[269.1] Patient-reported outcomes (PROs) are also gaining recognition in early clinical development, particularly for informing dose selection. Despite their potential benefits, PROs are infrequently included in the labeling of oncology drugs in the United States, although they are more prevalent in Europe and for non-oncology drugs.[268.1]In this section:
References
[1] History of Immunotherapy: Cancer Treatment - Oncodaily — History of Immunotherapy: Cancer Treatment. Immunotherapy. Immunotherapy is a revolutionary approach to cancer treatment that harnesses the power of the body's own immune system to combat malignant cells. It involves stimulating or enhancing the immune system's ability to recognize and destroy cancer cells while leaving healthy cells unharmed.
[2] History of Immunotherapy: Key Milestones and Breakthroughs — Explore the development of immunotherapy, from early immune response observations to its integration into modern oncology treatments. From early observations of immune responses against tumors to laboratory experiments and clinical applications, each milestone brought it closer to integration into standard oncology care. As microscopy and pathology advanced in the early 20th century, researchers identified immune cells infiltrating tumors, raising questions about their function. Despite these challenges, IL-2 demonstrated that immune-based treatments could produce meaningful outcomes in advanced cancers. Oncologists incorporated checkpoint inhibitors, monoclonal antibodies, and adoptive cell therapies into clinical guidelines, often tailoring their use based on tumor biomarkers and genetic profiling.
[3] The history and advances in cancer immunotherapy ... - Nature — Advertisement View all journals Search Log in Explore content About the journal Publish with us Sign up for alerts RSS feed nature cellular & molecular immunology review articles article The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications Download PDF Download PDF Review Article Open access Published: 01 July 2020 The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications Yuanyuan Zhang1 & Zemin Zhang1,2 Cellular & Molecular Immunology volume 17, pages 807–821 (2020)Cite this article 122k Accesses 330 Altmetric Metrics details Subjects Cancer microenvironment Tumour immunology Abstract Immunotherapy has revolutionized cancer treatment and rejuvenated the field of tumor immunology. Several types of immunotherapy, including adoptive cell transfer (ACT) and immune checkpoint inhibitors (ICIs), have obtained durable clinical responses, but their efficacies vary, and only subsets of cancer patients can benefit from them. In this review, we outline the recent progress in cancer immunotherapy, particularly by focusing on landmark studies and the recent single-cell characterization of tumor-associated immune cells, and we summarize the phenotypic diversities of intratumoral immune cells and their connections with cancer immunotherapy. Immunotherapy, aiming to boost natural defenses to eliminate malignant cells, is a monumental breakthrough for cancer treatment and has revolutionized the field of oncology.
[4] A Brief History of Immunotherapy - Targeted Oncology — Allison is the director of the immunotherapy platform at The University of Texas MD Anderson Cancer Center. IL-2 Antibody Therapies Vaccines. The idea of using immunotherapy in cancer, in general, returned to prominence when Thomas and Burnet first proposed the theory of cancer immunosurveillance in 1957.
[5] The Intriguing History of Cancer Immunotherapy - PubMed — Immunotherapy is often perceived as a relatively recent advance. In reality, however, one should be looking for the beginnings of cancer immunotherapy under different names as far as in the Antiquity. The first scientific attempts to modulate patients' immune systems to cure cancer can be attributed …
[6] The Intriguing History of Cancer Immunotherapy - PMC — His achievements were largely unnoticed for over fifty years, and several seminal discoveries in the field of Immunology, such as the existence of T cells and their crucial role in immunity in 1967, stepped up the research toward cancer immunotherapy known today. When expressed on the tumor site they allow cancer cells to evade immune responses so immune checkpoint blockage was a crucial breakthrough in cancer treatment (6). Many types of cancer cells can express specific ligands for immunosuppressive checkpoint proteins on their surface, thus preventing the immune system from attacking the growing tumor (22). Being highly immunogenic, they can activate CD4+ and CD8+ immune response, providing a perfect target for T cell based cancer immunotherapies (81). 10.1016/j.cell.2017.01.017 [DOI] [PMC free article] [PubMed] [Google Scholar]
[7] History of Cancer Treatments: Immunotherapy — Clinical trials have shown that this cancer treatment, called biological response modifier (BRM) therapy, biologic therapy, biotherapy, or immunotherapy, is effective for many types of cancer. Some of these biologic agents, which occur naturally in the body, can now be made in the lab.
[8] A review of cancer immunotherapy: from the past, to the present, to the ... — In this review article, we highlight the current standards of care in cancer immunotherapy, with a strong focus on immune checkpoint inhibitors (icis), their limitations and pitfalls, and promising novel approaches. Despite promising results with icis, single-agent PD-1 inhibitor has an objective response rate that varies from almost nonexistent in pancreatic cancer and microsatellite-stable colonic adenocarcinoma, to an average of 15%–30% in most other tumour types, but 50%–80% in melanoma, Hodgkin lymphoma, squamous-cell carcinoma of the skin, and Merkel cell carcinoma. In colorectal cancers, immune cell infiltration into the tumour microenvironment has been correlated with a strong immune response to treatment with icis, with even better correlation than for microsatellite instability39,40. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer.
[13] Impact of nanoparticles on immune cells and their potential ... — It is to be noted that much ongoing research aims to thoroughly comprehend the dynamic interplay between the immune system and cancer, leading to strategies that bolster immunotherapy effectiveness, surmount challenges, enhance patient responses, and establish immunotherapy as a fundamental pillar of cancer treatment .
[14] Global research trends of immunosenescence and immunotherapy: A ... — Thematic analysis enables the identification of primary research themes and development trends in immunosenescence and immunotherapy. It reveals that immune checkpoint inhibitors and immunosenescence are prominent research hotspots, Citation 7-52, Citation 53-54 garnering extensive attention for their applications and mechanisms. As
[15] Current advances in immunotherapy for cancer - ScienceDirect — Search ScienceDirect open access Recent advances in cancer immunotherapy, including immune checkpoint inhibitors (ICIs) and chimeric antigen receptor (CAR) T-cell therapy, have significantly improved the clinical management of various cancers. ICIs, such as PD-1/PD-L1 and CTLA-4 inhibitors, enhance the body's immune response against tumors, offering substantial benefits in cancers like melanoma, non-small-cell lung cancer, and lymphoma. To address these issues, ongoing research is exploring combination therapies that integrate ICIs with CAR-T cell therapy, improved CAR-T cell engineering, and strategies to modulate the tumor microenvironment to enhance immune cell infiltration and function. Previous article in issue Next article in issue Recommended articles No articles found. Article Metrics View article metrics For all open access content, the Creative Commons licensing terms apply.
[44] Cancer Immunoediting in the Era of Immuno-oncology - PMC — A) Cancer immunoediting was initially described during natural immune-tumor cell interactions in the absence of immunotherapy. Targeting this local, dysfunctional immune response within the tumor microenvironment with anti-PD-1 or anti-PD-L1 immunotherapy, reduces the T cell inhibition, allowing the T cells to become re-activated and eliminate cancer cells through cytokines (IFN-γ, TNFα) and cytolytic programs with perforin (PFN) and granzyme B (GzmB). There needs to be a continued focus on the dynamic immune cell and tumor cell interactions within the TME, the underlying principle of cancer immunoediting, to identify mechanisms of immunotherapy resistance and employ strategies to overcome resistance.
[45] Cancer Immunoediting in the Era of Immuno-oncology — Abstract. Basic science breakthroughs in T-cell biology and immune-tumor cell interactions ushered in a new era of cancer immunotherapy. Twenty years ago, cancer immunoediting was proposed as a framework to understand the dynamic process by which the immune system can both control and shape cancer and in its most complex form occurs through three phases termed elimination, equilibrium, and
[47] From past to present: The evolution of immunotherapy and its modern ... — Fig. 1 represents a schematic timeline of the development of immunotherapy. The timeline shows significant advancements in immunotherapy spanning over a century. It begins with the discovery of serum therapy for infectious diseases in 1890, followed by the synthesis of antibiotics in 1928 and the treatment of bone cancer using immunotherapy in
[48] Cancer and the Immune System: The History and Background of Immunotherapy — Timeline and Types of Immunotherapy Development Toxins and tumor necrosis factor In the 1930s and 1940s until the early 1960s bacteria was again used with intermittent success to treat tumors by causing necrosis. 21 Tumor necrosis factor (TNF), also identified as a cancer immunotherapy in the 1970s, was thought be a major development in cancer
[49] FDA Approval Timeline of Active Immunotherapies | CRI — The clinical development of active immunotherapies has exploded in the last ten years. Checkpoint inhibitors, in particular PD-1 and PD-L1, have been integrated into standard-of-care across many cancer types. ... Timeline of Anti-PD-1/L1 Antibody Approvals by the European Medicines Agency (EMA) for the European Union (EU), National Medical
[53] History of Immunotherapy: Key Milestones and Breakthroughs — Explore the development of immunotherapy, from early immune response observations to its integration into modern oncology treatments. From early observations of immune responses against tumors to laboratory experiments and clinical applications, each milestone brought it closer to integration into standard oncology care. As microscopy and pathology advanced in the early 20th century, researchers identified immune cells infiltrating tumors, raising questions about their function. Despite these challenges, IL-2 demonstrated that immune-based treatments could produce meaningful outcomes in advanced cancers. Oncologists incorporated checkpoint inhibitors, monoclonal antibodies, and adoptive cell therapies into clinical guidelines, often tailoring their use based on tumor biomarkers and genetic profiling.
[94] Immunotherapy by Treatment Types - Cancer Research Institute — Immunotherapy has shown remarkable success in treating advanced cases of cancers like lung cancer, melanoma, advanced bladder, and kidney cancer, amongst others. It's important to note that the list of cancers treatable with immunotherapy continues to grow as more drugs undergo clinical trials.
[95] Advances in cancer immunotherapies - Cell Press — Therapeutic modalities that engage the immune system to recognize and eliminate cancer, known as cancer immunotherapy, has emerged as a distinct pillar of cancer therapy. Among the most promising treatment approaches are therapeutic vaccines, immune checkpoint blockade, bispecific T-cell engagers (BiTEs) and adoptive cell therapies. These approaches share a common mechanism of action, which is
[96] Editorial: Personalized immunotherapy for cancer - PMC — Personalized therapies may harness the specific characteristics of each tumor to obtain a better clinical outcome compared to traditional treatment approaches. Immunotherapy is one of the promising approaches for personalized treatment; Adoptive cell therapy and neoantigen vaccines are two examples on how the immune system can be used and
[98] Personalized immunotherapy in cancer precision medicine - PMC — We found that patients with DNA repair gene mutations, resulting in higher TMB, showed significantly better recurrence-free survival than patients without DNA repair gene mutations (hazard ratio, 0.46; P = 0.044) and that an oligoclonal expansion of tumor-infiltrating T cells, represented by lower TCR diversity, was observed in tumors with higher neoantigen load in WES data of 78 patients with muscle-invasive bladder cancer43,44. Recently, Ott et al.81 conducted a clinical trial for personalized neoantigen vaccines with anti-PD-1 antibodies in 60 patients with melanoma, non-small cell lung cancer (NSCLC), or bladder cancer and found that neoantigen-specific CD4+ and CD8+ T-cell responses were observed in all of the patients and that objective response rates were 59%, 39%, and 27% for melanoma, NSCLC, and bladder cancer, respectively.
[99] Immunotherapy vs. Traditional Therapies: A New Frontier in Healthcare — Explore the differences between immunotherapy & traditional cancer treatments. Understand how this innovative therapy offers targeted, longer-lasting effects with fewer side effects. ... Immunotherapy: A New Approach. While other therapies target cancer cells and tumors themselves, immunotherapy is a companion to the immune system of the body
[100] Immunotherapy and Chemotherapy: What's the Difference? — Immunotherapy can be used at various stages of cancer, but it is particularly effective in the later stages or for cancers that have not responded well to traditional treatments. It's increasingly being used as part of first-line treatment in cancers like melanoma and lung cancer, where it has shown significant benefits.
[101] Combining Immunotherapy and Targeted Therapies in Cancer Treatment — More recently, an improved understanding of cancer pathogenesis has given rise to new treatment options, including targeted agents and cancer immunotherapy. Targeted approaches aim to inhibit molecular pathways that are critical to tumor growth and maintenance, whereas immunotherapy endeavors to stimulate a host response that effectuates long
[102] Immunotherapy Drug Development Pipeline Shifts from Traditional ... — DONATE NOW Search for: Close search Cancer Research Institute Media Room Subscribe Share Immunotherapy Drug Development Pipeline Shifts from Traditional Therapies to Newer Modalities April 18, 2023April 18, 2023 NEW YORK, NY, APRIL 18, 2023 NEW YORK – After years of broad and rapid growth, immuno-oncology (IO) clinical trials seem to be shifting from the traditional heavyweights to new directions, according to the latest update of the global IO Landscape Analysis published in Nature Reviews Drug Discovery by the Cancer Research Institute (CRI) Anna-Maria Kellen Clinical Accelerator. Overall, while the number of new IO trials dropped for the first time since this analysis began in 2018, a record number of IO targets (195) are being investigated in clinical trials launched in 2022. This latest analysis examined 9,007 IO trials that began between 2018 and 2022 and observed a 2.86% decrease in new trials in 2022 compared to 2021, driven by a 6.4% decrease in phase 2 trials. Among all trials, there was a 10.3% decrease in those using PD-1/PD-L1 inhibitors, whereas other targets like CTLA-4, LAG-3, and CD3 T cell-engager increased 17.9%, 36.8%, and 13.3%, respectively. The scope of IO-based therapies also expanded, with the number of therapeutic targets expanding from 146 in 2020, to 160 in 2021, to 195 targets now in 2022.
[115] Challenges and opportunities in cancer immunotherapy: a Society for ... — This group collaboratively defined nine major hurdles to progress in the landmark white paper, “Defining the critical hurdles in cancer immunotherapy”14: (1) limitations of current animal models to predict efficacy of cancer immunotherapy strategies in humans; (2) prolonged time to obtain approval to initiate clinical trials; (3) complexity of cancer, tumor heterogeneity, and immune escape; (4) limited availability of reagents for combination immunotherapy studies; (5) limited funds available to translate science into patients; (6) lack of definitive biomarker(s) for the assessment of clinical efficacy of cancer immunotherapies; (7) conventional clinical response criteria that do not take into consideration differences between response patterns to cytotoxic agents and immunotherapies; (8) paucity of teams of scientists and clinicians dedicated to translational research in cancer immunotherapy; and (9) insufficient exchange of information critical to advancing the field.
[116] Top 10 Challenges in Cancer Immunotherapy - PubMed — Top 10 Challenges in Cancer Immunotherapy - PubMed Search: Search Your saved search Name of saved search: Here, we define ten key challenges facing cancer immunotherapy, which range from lack of confidence in translating pre-clinical findings to identifying optimal combinations of immune-based therapies for any given patient. Addressing these challenges will require the combined efforts of basic researchers and clinicians, and the focusing of resources to accelerate understanding of the complex interactions between cancer and the immune system and the development of improved treatment options for patients with cancer. Keywords: CAR T; T cell engagers; adaptive immune resistance; biomarkers; bispecific antibodies; cancer immune phenotypes; cancer immunotherapy; cellular therapy; immuno-oncology; intrinsic immune resistance; primary immune escape; secondary immune escape; synthetic immunity; tumor mutational burden.
[117] Challenges and shifting paradigms in clinical trials in oncology: the ... — Due to this rapid increase in knowledge and pharmaceutical development, traditional clinical trials designs have encountered major limitations. The pharmacological differences (in toxicity profiles and effectiveness patterns) between immunotherapy and chemotherapy have caused traditional clinical trials to evolve in order to meet this emerging
[124] Patients' experiences of cancer immunotherapy with immune checkpoint ... — Patients' experiences of cancer immunotherapy with immune checkpoint inhibitors: A systematic review and thematic synthesis - PubMed Patients' experiences of cancer immunotherapy with immune checkpoint inhibitors: A systematic review and thematic synthesis Patients' experiences of cancer immunotherapy with immune checkpoint inhibitors: A systematic review and thematic synthesis Results: Eighteen papers were included and three analytical themes developed: immune checkpoint inhibitor treatment decision-making; the experience and impact of immune checkpoint inhibitor treatments; and appraising and responding to irAEs. Conclusion: The synthesis renders visible individuals' unmet information, psychological and practical support needs. Keywords: cancer; immune checkpoint inhibitors; patient experience; qualitative research; systematic review. Experience of patients considering or using checkpoint inhibitors in cancer treatment: a systematic review of qualitative research.
[125] Patients' experiences of cancer immunotherapy with immune checkpoint ... — ICIs are transforming survival outcomes for many with certain advanced cancers. Given the possibility of unique immune-related adverse events (irAEs), understanding treatment experiences is crucial to identify support needs and provide safe and effective person-centred care. Design. A systematic review of qualitative research and thematic
[126] Experience of patients considering or using checkpoint inhibitors in ... — Increasing numbers of patients with cancer are considering or undergoing immunotherapy, however, little is known about patients' perspectives on this treatment. We undertook a systematic review for use by clinicians and researchers, consolidating published qualitative research studies on patient experience of checkpoint inhibitor therapy.
[127] Experiences of cancer immunotherapy with immune checkpoint inhibitors ... — However, it has been noted that existing cancer decision-making pathways for some patients focus on clinical management of disease rather than patients' preferences and priorities for cancer treatment. 46 Limited literature examines the immunotherapy decision-making process, for patients across all tumour sites and at various stages of disease.
[134] Immunotherapy by Treatment Types | Cancer Research Institute — Immunotherapy by Treatment Types | Cancer Research Institute Immunotherapy by Cancer Type Cancer Immunotherapy Month Immunotherapy by Cancer Type Cancer Immunotherapy Month Adoptive Cell Therapy --------------------- Adoptive cell therapy is a type of cancer treatment that reactivates, enhances, and expands naturally occurring, cancer-fighting immune cells… Targeted Antibodies ------------------- Targeted antibodies are a type of immunotherapy that can disrupt cancer cell activity and alert the immune system to… What types of cancer does immunotherapy treat? Cancer vaccines are a form of immunotherapy that educates the immune system about cancer cells, enabling it to recognize and destroy them. Oncolytic virus therapy marks a unique approach within immunotherapy, utilizing viruses that specifically infect and destroy cancer cells.
[135] Immunotherapy for Cancer - NCI — Immunotherapy for Cancer - NCI Skip to main content An official website of the United States government Español Menu Search Search About Cancer Cancer Types Research Grants & Training News & Events About NCI Home About Cancer Cancer Treatment Types of Cancer Treatment Immunotherapy to Treat Cancer Print Email) Cancer Treatment Types of Cancer Treatment Biomarker Testing Chemotherapy Hormone Therapy Hyperthermia Immunotherapy Cancer Treatment Vaccines Checkpoint Inhibitors Immune System Modulators Monoclonal Antibodies Side Effects T-cell Transfer Therapy Photodynamic Therapy Radiation Therapy Stem Cell Transplant Surgery Targeted Therapy Side Effects of Cancer Treatment A to Z List of Cancer Drugs Complementary & Alternative Medicine (CAM) Questions to Ask about Your Treatment NIH Clinical Center Research Immunotherapy to Treat Cancer Immunotherapy is a type of cancer treatment that helps your immune system fight cancer. The immune system helps your body fight infections and other diseases. Immunotherapy helps the immune system to better act against cancer. Several types of immunotherapy are used to treat cancer. Immunotherapy drugs have been approved to treat many types of cancer.
[136] Types of Immunotherapy for Cancer - WebMD — Immunotherapy is an umbrella term for cancer treatments that harness your own immune system. Learn how different types of immunotherapy work.
[137] Immunotherapy - StatPearls - NCBI Bookshelf — Immunotherapy is the use of drugs (eg, immunosuppressors), biologicals (eg, cytokines, monoclonal antibodies, and antisera), vitamins and minerals (eg, zinc, vitamin C, and vitamin B6), transplantation (eg, bone marrow), and immunizations (eg, prophylactic and therapeutic vaccines) to control immune responses. For example, immunotherapy works to upregulate or downregulate the immune system to achieve a therapeutic effect in immunologically mediated disorders, including immunodeficiencies, hypersensitivity reactions, autoimmune diseases, tissue and organ transplantations, malignancies, inflammatory disorders, infectious diseases, and any other disease, where immunotherapy can improve the quality and life expectancy. Adverse effects of immunotherapy include: Providing care to patients with immune deficiencies is most effective with an interprofessional team that includes clinicians (MDs, DOs, NPs, PAs), specialists, hematology nurses, and pharmacists.
[147] Immunotherapy: Pushing the Frontier of Cancer Medicine | AACR Cancer ... — Supporting Cancer Patients and Survivors Envisioning the Future of Cancer Science and Medicine Advancing Cancer Research and Patient Care Through Evidence-based Policies Conclusion AACR Call to Action AACR President’s Vision: A Healthier Future for All Cancer Patients AACR Initiatives Accelerating Cancer Research Steering Committee References Survivors Previous Editions Graphics About the Report Get a Copy Home > AACR Cancer Progress Report > AACR Cancer Progress Report 2023: Contents > Spotlight on Immunotherapy: Pushing the Frontier of Cancer Medicine Spotlight on Immunotherapy: Pushing the Frontier of Cancer Medicine In this section, you will learn: Cancer immunotherapeutics work by unleashing the power of a patient’s immune system to fight cancer and, over the last decade, have emerged as one of the most exciting new approaches to cancer treatment. Immune checkpoint inhibitors (ICIs) work by releasing the brakes on the natural cancer-fighting power of the immune system. As of July 31, 2023, the FDA has approved 11 ICIs, and there is at least one ICI approved for treating 20 cancer types and for treating any type of solid tumors that share certain molecular characteristics. CAR T-cell therapy provides more cancer-targeted immune cells called T cells. As of July 31, 2023, the FDA has approved six distinct CAR T-cell therapies for the treatment of a range of hematologic cancers.
[149] Emerging Cancer Immunotherapies: Cutting-Edge Advances and ... - MDPI — Immunotherapy has emerged as an advanced treatment approach for a range of cancers, encompassing both hematological malignancies and solid tumors. This strategy harnesses the patient's immune system to combat cancer, offering a pathway to more targeted and efficient treatments. Compared to chemotherapy, immunotherapy is associated with fewer side effects, making it a promising therapeutic
[163] New Immunotherapy Treatment Brings Hope to Patients With Advanced Non ... — Although immunotherapies have shown promise in treating non-small cell lung cancer (NSCLC), many patients still do not respond well, and those who do may eventually develop resistance. In a new study, Yale Cancer Center researchers at Yale School of Medicine tested a new immunotherapy, NC318, in combination with the targeted immunotherapy, pembrolizumab (KEYTRUDA).
[178] Role of Immunotherapy in the Treatment of Cancer: A Systematic Review — The results from the present study indicate that the use of immunotherapy, either alone or as a supportive therapy to the conventional cancer treatments, has enormous potential in improving the overall survival and progression-free survival rates of cancer patients, especially those who have failed on their first-line therapy, leading to disease recurrence. 15.Hui R., Garon E.B., Goldman J.W., Leighl N.B., Hellmann M.D., Patnaik A., Gandhi L., Eder J.P., Ahn M.-J., Horn L., et al. 68.Pallin D.J., Baugh C.W., Postow M.A., Caterino J.M., Erickson T.B., Lyman G.H. Immune-related Adverse Events in Cancer Patients. 70.Ramirez R.A., Lu J., Thomas K.E.H. Quality of life for non-small cell lung cancer patients in the age of immunotherapy.
[183] A review of cancer immunotherapy: from the past, to the present, to the ... — In this review article, we highlight the current standards of care in cancer immunotherapy, with a strong focus on immune checkpoint inhibitors (icis), their limitations and pitfalls, and promising novel approaches. Despite promising results with icis, single-agent PD-1 inhibitor has an objective response rate that varies from almost nonexistent in pancreatic cancer and microsatellite-stable colonic adenocarcinoma, to an average of 15%–30% in most other tumour types, but 50%–80% in melanoma, Hodgkin lymphoma, squamous-cell carcinoma of the skin, and Merkel cell carcinoma. In colorectal cancers, immune cell infiltration into the tumour microenvironment has been correlated with a strong immune response to treatment with icis, with even better correlation than for microsatellite instability39,40. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer.
[184] Studies Show Immunotherapy Improves Long-Term Survival in Growing ... — Immunotherapy, which works by enabling the body's immune system to recognize and destroy cancer cells, improves long-term overall survival in patients with advanced melanoma in results from large international studies reported at the European Society for Medical Oncology Congress (#ESMO2024).. Researchers leading the longest follow-up study to date suggest that immunotherapy offers the
[185] Studies Show Immunotherapy Improves Long-Term Survival in Growing — Results of a phase 3 trial of immunotherapy with an anti-programmed death (PD)-1-based therapy showed continued long-term survival benefit in patients with advanced melanoma. (1) After follow-up of at least 10 years, the median overall survival was 71.9 months (about 6 years) in patients randomised to combination immunotherapy with
[186] The Long-Term and Short-Term Efficacy of Immunotherapy in Non-Small ... — In the new era of immunotherapy, our meta-analysis validated the importance of immunotherapy for non-small cell lung cancer (NSCLC) patients with brain metastases (BMs). By comparing the long-term and short-term impacts of various regimens, all immunotherapy treatments had superior efficacy to immunotherapy-naive.
[187] Scientists Identify 5 Key Factors That Predict Cancer Immunotherapy Success — Researchers at IRB Barcelona identified five key factors—tumor mutational burden, T-cell infiltration, TGF-β activity, previous treatment, and tumor proliferative potential—that influence response to immunotherapy, offering a path toward more personalized cancer care. Researchers identified five factors that predict response to immunotherapy, advancing personalized cancer treatment. Researchers at IRB Barcelona have identified five key, independent factors that determine patients’ response and survival after receiving checkpoint inhibitors (CPIs), a type of immunotherapy widely used in cancer treatment. “We used an unbiased approach to analyze thousands of molecular and clinical features and identified five independent factors that influence response to immunotherapy and patient survival,” explains Dr. López-Bigas, ICREA researcher at IRB Barcelona.
[188] Long term benefits of immunotherapy emerging for some patients, though ... — Follow-up of a small, early-phase trial of advanced non-small cell lung cancer (NSCLC) patients offered some idea of the potential long-term benefits of immunotherapy for those patients whose tumours responded. Around 16% were still alive 5 years after starting treatment with nivolumab, compared to 5% as would be expected of the US patient group.
[189] Studies Show Immunotherapy Improves Long-Term Survival in Growing ... — Immunotherapy, which works by enabling the body's immune system to recognize and destroy cancer cells, improves long-term overall survival in patients with advanced melanoma in results from large international studies reported at the European Society for Medical Oncology Congress (#ESMO2024).. Researchers leading the longest follow-up study to date suggest that immunotherapy offers the
[190] Cost effectiveness of immune checkpoint inhibitors for treatment of non ... — Immunotherapy can be a cost-effective option for treatment of NSCLC in several scenarios. A discount of the agents or the use of PD-L1 expression as a biomarker improves the cost-effectiveness of immunotherapy. Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review
[191] Cost-effectiveness of immune checkpoint inhibitors in NSCLC according ... — A major concern for immunotherapy in NSCLC is the high cost of treatment. Nivolumab cost per milligram was US$24.69, the cost per cycle was around US$5184 and the cost per year of treatment can reach up to US$134,807. ... As noted above, the PD-L1 cutoff point of 50% further optimized the cost-effectiveness of treatment; however, it seems
[192] Cost-Effectiveness of Treatment Optimisation with Biomarkers for ... — The focus was predominantly on non-small cell lung cancer (NSCLC) (65%) and other solid tumours (40%). Among the NSCLC studies, 21 out of 35 demonstrated cost-effectiveness, notably for pembrolizumab as first-line treatment when preceded by PD-L1 assessment, cost-effective at a threshold of $100,000/QALY compared to the standard of care.
[221] Immunotherapy Side Effects: Common, Severe & How to Manage — A key takeaway for any side effect of immunotherapy is to be aware of what to expect and have a management plan of action with the cancer care team. Knowing as much as possible about immunotherapy side effects and what to expect may help the patient feel more in control and at ease. Speaking with a counselor or psychologist may help the patient manage pain and cope with the stress and difficult thoughts often associated with cancer treatment. Fever and chills: After immunotherapy, the patient's temperature may spike to help regulate his or her body’s processes. If the patient is experiencing high blood pressure, speak with the care team to help find the most appropriate way to manage it.
[223] Immunotherapy: Side Effects, Risks & Benefits - Cleveland Clinic — Immunotherapy Side Effects Immunotherapy Side Effects Immunotherapy is designed to strengthen your immune system to fight cancer more effectively. Immunotherapy is a cancer treatment that uses your body’s immune system to find and destroy cancer cells. Helping your body produce cancer-fighting immune cells that effectively locate and destroy cancer cells. Immunotherapy is an effective treatment for many forms of cancer because it strengthens the immune defenses you already have. Why does immunotherapy cause side effects? As a result, immunotherapy can cause inflammation in healthy tissue that you may experience as one or more side effects. Most research on side effects has focused on a particular type of immunotherapy called immune checkpoint inhibitors (ICI). CAR T-cell therapy may also cause side effects that affect your immune system, including:
[224] Side Effects of Immunotherapy - NCI - National Cancer Institute — Side Effects of Immunotherapy - NCI About Cancer Cancer Types About Cancer Cancer Treatment Types of Cancer Treatment Immunotherapy Side Effects Cancer Treatment Types of Cancer Treatment Side Effects of Cancer Treatment Immunotherapy Side Effects Immunotherapy can cause side effects. Many side effects happen when the immune system that is revved-up to act against the cancer also acts against healthy cells and tissues in the body. your type of cancer Some side effects are common with all types of immunotherapy. ### Investigating Cancer Immunotherapy Side Effects Researchers aim to better understand, manage the side effects of these new drugs. Certain side effects might happen depending on the type of immunotherapy you receive. 1-800-4-CANCER
[225] Management of toxicities from immunotherapy: ESMO Clinical Practice ... — Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆ - Annals of Oncology Adverse events (AEs) related to the use of immune checkpoint inhibitor (ICI) therapy are defined as immune-related (IR) AEs (irAEs). irAEs are graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 (Supplementary Table S1, available at https://doi.org/10.1016/j.annonc.2022.10.001).1 The aim of this European Society for Medical Oncology (ESMO) Clinical Practice Guideline (CPG) is to provide specific guidance on irAE management. ∙ Cappelli, L.C. Rheumatic immune-related adverse events from cancer immunotherapy Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline ∙ Perazella, M.A. Immune checkpoint inhibitors and immune-related adverse renal events
[226] Understanding Side Effects of Chemotherapy & Immunotherapy — Understanding side effects is not merely a clinical matter; it encompasses emotional, social, and psychological aspects of patient care. Focusing on patient-centric considerations enables healthcare providers to tailor treatments that best suit individual needs, improving overall well-being and treatment outcomes.
[229] Managing Your Immunotherapy Side Effects | Memorial Sloan Kettering ... — Managing Your Immunotherapy Side Effects This information will help you manage the side effects from your immunotherapy. Immunotherapy is a form of cancer treatment that uses your immune system to attack cancer cells. The side effects from immunotherapy treatment may be different from chemotherapy. Fatigue may be caused by changes to the thyroid gland by immunotherapy. When diarrhea is caused by immunotherapy it is called immune-related (IR) colitis (swelling of the large intestine). For more information about how to manage mouth sores, read Mouth Care During Your Cancer Treatment. Immunotherapy can cause changes to your skin. Immunotherapy uses your immune system to attack cancer cells. There is a group of side effects you may get from immunotherapy called immune-related (IR) side effects
[230] Immunotherapy Side Effects: Managing and Coping Strategies - DarwynHealth — Immunotherapy can have psychological and emotional effects on patients undergoing treatment. These effects may include anxiety, depression, and mood swings. It is important for patients to be aware of these potential side effects and to seek support from their loved ones and healthcare professionals.
[231] Anxiety among immunotherapy patients: Preliminary findings from ... — Background: Immunotherapy is a relatively new method of cancer treatment which has seen little research into its psychosocial side effects. A clearer understanding of the source of anxiety for those undergoing immunotherapy is crucial as anxiety during cancer treatment can result in decreased treatment adherence, increased mortality rates, and other negative outcomes.
[260] Immunotherapy Drug Development Pipeline Shifts from Traditional ... — DONATE NOW Search for: Close search Cancer Research Institute Media Room Subscribe Share Immunotherapy Drug Development Pipeline Shifts from Traditional Therapies to Newer Modalities April 18, 2023April 18, 2023 NEW YORK, NY, APRIL 18, 2023 NEW YORK – After years of broad and rapid growth, immuno-oncology (IO) clinical trials seem to be shifting from the traditional heavyweights to new directions, according to the latest update of the global IO Landscape Analysis published in Nature Reviews Drug Discovery by the Cancer Research Institute (CRI) Anna-Maria Kellen Clinical Accelerator. Overall, while the number of new IO trials dropped for the first time since this analysis began in 2018, a record number of IO targets (195) are being investigated in clinical trials launched in 2022. This latest analysis examined 9,007 IO trials that began between 2018 and 2022 and observed a 2.86% decrease in new trials in 2022 compared to 2021, driven by a 6.4% decrease in phase 2 trials. Among all trials, there was a 10.3% decrease in those using PD-1/PD-L1 inhibitors, whereas other targets like CTLA-4, LAG-3, and CD3 T cell-engager increased 17.9%, 36.8%, and 13.3%, respectively. The scope of IO-based therapies also expanded, with the number of therapeutic targets expanding from 146 in 2020, to 160 in 2021, to 195 targets now in 2022.
[262] Experts Forecast Cancer Research and Treatment Advances in 2023 - AACR — Experts Forecast Cancer Research and Treatment Advances | Blog | AACR × Advanced Search Search for: Select "Patients / Caregivers / Public" or "Researchers / Professionals" to filter your results. The U.S. Food and Drug Administration (FDA) issued 40 drug approvals for oncology indications, 12 of which were new, first-in-human molecules. Among other promising news, the results of a groundbreaking and potentially practice-changing immunotherapy clinical trial showed that an immune checkpoint inhibitor given to patients with locally advanced rectal cancer with a certain defect in DNA repair led to a complete clinical response with no evidence of residual disease, sparing the patients from chemoradiotherapy and surgery. Thanks to the advances in cancer research and care in the past decades, in early 2022, the number of cancer survivors in the U.S. surpassed an estimated 18 million. In keeping with a new-year tradition on the AACR blog, we asked a group of experts to discuss the state of the art in their fields of research and to share their predictions for the next significant developments in the year 2023 in immunotherapy, precision medicine, prevention and early detection, patient advocacy, and cancer health disparities.
[263] Current advances in immunotherapy for cancer - ScienceDirect — Search ScienceDirect open access Recent advances in cancer immunotherapy, including immune checkpoint inhibitors (ICIs) and chimeric antigen receptor (CAR) T-cell therapy, have significantly improved the clinical management of various cancers. ICIs, such as PD-1/PD-L1 and CTLA-4 inhibitors, enhance the body's immune response against tumors, offering substantial benefits in cancers like melanoma, non-small-cell lung cancer, and lymphoma. To address these issues, ongoing research is exploring combination therapies that integrate ICIs with CAR-T cell therapy, improved CAR-T cell engineering, and strategies to modulate the tumor microenvironment to enhance immune cell infiltration and function. Previous article in issue Next article in issue Recommended articles No articles found. Article Metrics View article metrics For all open access content, the Creative Commons licensing terms apply.
[265] Translating Immunopeptidomics to Immunotherapy‐Decision‐Making for ... — Mass spectrometry enables the direct and unbiased discovery and selection of tumor‐specific human leukocyte antigen (HLA) peptides that can be used to define targets for immunotherapy. Combining these targets into a warehouse allows for multi‐target therapy and accelerated clinical application.
[266] Immunotherapy and next-generation sequencing guided therapy for ... — Several investigators have reported a favorable response to immunotherapy in patients who exhibit a high mutational burden. Roszik et al developed a novel way to predict total mutational load using a small NGS panel and found that this method could strongly predict outcomes to immunotherapy in both melanoma and NSCLC[ 59 ].
[267] Application and Expectations for Immune Checkpoint Blockade of LAG3 and ... — Additionally, we address the emerging challenges such as treatment resistance and adverse effects. We explore the strategic integration of LAG3 and TIGIT blockade within the broader immunotherapy landscape, emphasizing innovative combinations and the quest for predictive biomarkers to optimize patient selection and treatment efficacy.
[268] Immunotherapy and Novel Combinations in Oncology: Current Landscape ... — The use of patient‐reported outcomes (PRO) to inform dose selection are also recommended in early clinical development, given the tolerability and adherence issues associated with these drugs, although PROs are rarely included in the labeling of oncology drugs in the US (although they are more common in Europe and for nononcology drugs in the
[269] Immuno-Oncology: New Insights into Targets and Therapies — The role of immunotherapy in the care of surgical oncology patients promises to expand as investigators and clinicians evaluate new targets and approaches. Currently active clinical trials evaluate new immune checkpoints, including lymphocyte activation gene 3, T cell immunoreceptor with Ig and ITIM domains, and killer Ig-like receptor 2DL1/2L3.
[291] Current Landscape and Future Directions in Cancer Immunotherapy ... — However, challenges such as immunotherapy resistance, patient response variability, and the need for improved biomarkers limit its widespread success. This review provides a comprehensive analysis of the current landscape of cancer immunotherapy, highlighting both FDA-approved therapies and novel approaches in clinical development.
[292] Challenges and opportunities in cancer immunotherapy: a Society for ... — This group collaboratively defined nine major hurdles to progress in the landmark white paper, “Defining the critical hurdles in cancer immunotherapy”14: (1) limitations of current animal models to predict efficacy of cancer immunotherapy strategies in humans; (2) prolonged time to obtain approval to initiate clinical trials; (3) complexity of cancer, tumor heterogeneity, and immune escape; (4) limited availability of reagents for combination immunotherapy studies; (5) limited funds available to translate science into patients; (6) lack of definitive biomarker(s) for the assessment of clinical efficacy of cancer immunotherapies; (7) conventional clinical response criteria that do not take into consideration differences between response patterns to cytotoxic agents and immunotherapies; (8) paucity of teams of scientists and clinicians dedicated to translational research in cancer immunotherapy; and (9) insufficient exchange of information critical to advancing the field.